Letters to the Editor
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
CMV Reactivations During and after Letermovir Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation: a Single-Center Experience.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: September 9, 2025
Accepted: September 30, 2025
Accepted: September 30, 2025
354
Views
218
Downloads
Authors
Downloads
Download data is not yet available.
Citations
Schmidt-Hieber, M. et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol 98, 1755–1763 (2019). https://doi.org/10.1007/s00277-019-03669-z
Ganepola, S. et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39, 293–299 (2007). https://doi.org/10.1038/sj.bmt.1705585
Stern, L. et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol 10, (2019). https://doi.org/10.3389/fmicb.2019.01186
Ljungman, P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 42, (2008). https://doi.org/10.1038/bmt.2008.120
Ljungman, P., Hakki, M. & Boeckh, M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24, 319–337 (2010). https://doi.org/10.1016/j.idc.2010.01.008
Marty, F. M. et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine 377, 2433–2444 (2017). https://doi.org/10.1056/NEJMoa1706640
Herrera, F. et al. Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina. Mediterr J Hematol Infect Dis 16, (2024). https://doi.org/10.4084/MJHID.2024.039
Gabanti, E. et al. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. Transplant Cell Ther 28, 211.e1-211.e9 (2022). https://doi.org/10.1016/j.jtct.2022.01.008
Liu, L. W. et al. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Transplant Cell Ther 28, 510.e1-510.e9 (2022). https://doi.org/10.1016/j.jtct.2022.05.020
Girmenia, C. et al. The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome after Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir Prophylaxis. Open Forum Infect Dis 12, (2025). https://doi.org/10.1093/ofid/ofaf233
Russo, D. et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 11, e127–e135 (2024). https://doi.org/10.1016/S2352-3026(23)00344-7
Spyridonidis, A. et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55, 1114–1125 (2020). https://doi.org/10.1038/s41409-020-0803-y
How to Cite
“CMV Reactivations During and after Letermovir Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation: a Single-Center Experience”. (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025079. doi:10.4084/MJHID.2025.079.
Copyright (c) 2025 Edoardo Olivari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
